US stock futures dip as Trump’s firing of Cook sparks Fed independence fears
Ryan Khouri, the CEO of CTT Pharmaceutical (TADAWUL:2070) Holdings, Inc. (OTC:CTTH), has acquired 5,200 shares of the company, according to a recent filing with the Securities and Exchange Commission. The shares were purchased on February 5 at a price of $0.12 each, amounting to a total transaction value of $624. Following this transaction, Khouri holds a total of 6,557,556 shares in the company. The purchase comes as CTTH shows strong momentum, with InvestingPro data revealing a remarkable 359% return over the past year and an "Excellent" financial health rating. The company, currently valued at $6.2 million, maintains strong liquidity with assets exceeding short-term obligations. For more detailed insights and analysis, including additional ProTips, check out InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.